Short-term decreased post transplant lymphoproliferative disorder risk after kidney transplantation using two novel regimens

•Two novel immunosuppressive regimens consisting of a standard regimen (B0) mycophenolate, tacrolimus and sirolimus and a belatacept-based regimen cohort (B1) mycophenolate, tacrolimus and belatacept.•No increased risk of PTLD with belatacept therapy.•Both cohorts benefited from low rejection rates.•Graft failure, mortality and malignancy at 12 and 24-months were similar.•CMV/BK viremia at rates were similar.